Lexicon Pharmaceuticals, Inc.(LXRX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$2.21
52-Week Range
$0.73 – $2.53
YTD
+94.30%
IV Rank (30D)
38.95
Straddle Price
$0.50
P/C Vol Ratio
0.81
Market Cap
$1.0B
Fair Value
-17.4% vs price
Confidence: 13% Alpha Score: 0.10

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.46%
Beta vs SPY1.00
Cost of Equity (CAPM)9.96% (VRP-adj)
WACC9.97%
Volatility Risk Premium+186.9pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-12.9%
Book / Price25.2%
Gross Margin (TTM)99.5%
FCF Margin (TTM)-55.8%
Debt / Equity0.24
Quality Score2/6 — normal (10y DCF)
SMA 50$1.94 (Market Anchor value)
SMA 20 / Bollinger Mid$2.00
Bollinger Width / SMA201190.1% (drives anchor stability)
Net Debt$0.0B
Market Cap$1B
Peers used for multiples: ACRS, ALKS, CCCC, CYRX, IART, MGTX, MRVI, XOMA
Blended Fair Value
$1.83
Current Price
$2.22
Deviation
-17.4%
Forward-Return Rank SHORT gated
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -3.1% +0.17 -0.59 67.6%
42d -6.6% -0.42 -0.59 67.6%
63d -8.4% -0.66 -0.59 67.6%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 37.2× · 3 peers
Peer EV/EBITDA n/a 0% median 38.2× · 3 peers
Peer P/B $1.99 50% median 3.7× · 7 peers
Peer P/S $1.68 50% median 9.0× · 8 peers
Market Anchor (SMA50) $1.94 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-24 · updated 2026-06-24 20:59:31.125000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$1.0B

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +4.04% 19
Feb -2.15% 19
Mar +0.42% 19
Apr -0.68% 20
May +4.77% 20
Jun +5.81% 20
Jul +3.54% 19
Aug -3.30% 19
Sep +4.09% 19
Oct -3.25% 19
Nov -0.91% 19
Dec +6.18% 19
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $2.01
SMA 50: $1.95
SMA 200: $1.54
Current: $2.22
EMA 12: $2.05
EMA 26: $2.01
MACD: 0.0393 | Signal: 0.0245
BULLISH
ADX (14): 18.41
RANGE
+DI: 28.13
−DI: 13.28
Momentum Oscillators
RSI (14): 64.58
NEUTRAL
Stoch %K: 90.38
Stoch %D: 79.87
Williams %R: -11.63
Volume & Volatility
BB Upper: $2.26
BB Lower: $1.75
NEUTRAL
OBV: 338,965,775
Vol SMA 20: 2,238,470
Vol ROC: 123.61%
ATR: $0.13
True Range: $0.11
HV 20: 56.0%
HV 30: 56.2%
HV 60: 73.4%

Data Summary
Data Points: 500
Last Updated: 2026-06-24T21:15:22.406000
Date Range: 2024-06-25T00:00:00 – 2026-06-24T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
6 of 7 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-01 Pre-Market 18.56% 13.53% 0.73x Within
2024-11-12 Pre-Market 39.06% 13.28% 0.34x Within
2025-05-13 After-Close 31.58% 13.21% 0.42x Within
2025-08-06 After-Close 17.39% 2.61% 0.15x Within
2025-11-06 After-Close 33.22% 12.59% 0.38x Within
2026-01-29 After-Close 34.84% 19.86% 0.57x Within
2026-05-07 After-Close 13.39% 18.45% 1.38x Exceeded
Options Activity
IV Rank (30D)
38.95
IV Rank (7D)
38.95
Avg IV
217.2%
Straddle (30D)
$0.50
Straddle (7D)
$0.50
P/C Volume
0.81
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.73
Correlation (SPY)
25.3%
0.06
Ann. Volatility
84.8%
SPY Volatility
12.5%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 372,565,500 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

141 filers323,504,315 shares$497.45M value86.83% of float
# Filer Shares Value % of Total % of Float Period
1 Artal Group S.A. 154,734,327 $241.39M 48.52% 41.53% 2026-03-31
2 FMR LLC Custodian 45,056,338 $70.29M 14.13% 12.09% 2026-03-31
3 Siren, L.L.C. 44,303,518 $69.11M 13.89% 11.89% 2026-03-31
4 Sessa Capital IM, L.P. 17,912,961 $27.94M 5.62% 4.81% 2026-03-31
5 Point72 Asset Management, L.P. 7,814,606 $12.19M 2.45% 2.10% 2026-03-31
6 VANGUARD GROUP INC Custodian 9,606,549 $11.05M 2.22% 2.58% 2025-12-31
7 MILLENNIUM MANAGEMENT LLC Custodian 4,944,731 $7.71M 1.55% 1.33% 2026-03-31
8 BlackRock, Inc. Custodian 3,322,219 $5.18M 1.04% 0.89% 2026-03-31
9 GEODE CAPITAL MANAGEMENT, LLC Custodian 3,169,111 $4.95M 0.99% 0.85% 2026-03-31
10 JANE STREET GROUP, LLC Custodian 2,665,938 $4.16M 0.84% 0.72% 2026-03-31
11 UBS Group AG Custodian 2,483,182 $3.87M 0.78% 0.67% 2026-03-31
12 MARSHALL WACE, LLP Custodian 2,376,304 $3.71M 0.75% 0.64% 2026-03-31
13 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian 2,121,164 $3.31M 0.67% 0.57% 2026-03-31
14 CIBC Bancorp USA Inc. 1,800,000 $2.81M 0.56% 0.48% 2026-03-31
15 RENAISSANCE TECHNOLOGIES LLC 1,600,500 $2.50M 0.50% 0.43% 2026-03-31
16 CIBC Private Wealth Group LLC 1,950,000 $2.24M 0.45% 0.52% 2025-12-31
17 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,311,298 $2.05M 0.41% 0.35% 2026-03-31
18 TWO SIGMA INVESTMENTS, LP 1,199,632 $1.87M 0.38% 0.32% 2026-03-31
19 CITADEL ADVISORS LLC Custodian 1,094,901 $1.71M 0.34% 0.29% 2026-03-31
20 GOLDMAN SACHS GROUP INC Custodian 1,070,517 $1.67M 0.34% 0.29% 2026-03-31
21 STATE STREET CORP 964,038 $1.50M 0.30% 0.26% 2026-03-31
22 Ishara Investments LP 902,000 $1.41M 0.28% 0.24% 2026-03-31
23 Hennion & Walsh Asset Management, Inc. 848,138 $1.32M 0.27% 0.23% 2026-03-31
24 MACKENZIE FINANCIAL CORP 772,677 $1.21M 0.24% 0.21% 2026-03-31
25 ADAR1 Capital Management, LLC 750,000 $1.17M 0.24% 0.20% 2026-03-31
6 filers$3.38M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $874.69K 25.89% 2026-03-31
2 JANE STREET GROUP, LLC Custodian $871.26K 25.79% 2026-03-31
3 CITADEL ADVISORS LLC Custodian $862.21K 25.52% 2026-03-31
4 GROUP ONE TRADING LLC Custodian $524.63K 15.53% 2026-03-31
5 SIMPLEX TRADING, LLC Custodian $206.23K 6.10% 2026-03-31
6 WOLVERINE TRADING, LLC Custodian $39.62K 1.17% 2025-09-30
6 filers$286.05K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $131.66K 46.03% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $61.93K 21.65% 2026-03-31
3 WOLVERINE TRADING, LLC Custodian $43.78K 15.31% 2025-09-30
4 JANE STREET GROUP, LLC Custodian $22.62K 7.91% 2026-03-31
5 GROUP ONE TRADING LLC Custodian $16.22K 5.67% 2026-03-31
6 SIMPLEX TRADING, LLC Custodian $9.83K 3.44% 2026-03-31
Insider Activity
Latest: 2026-06-04
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-04 CHRISTOPHER J SOBECKI Director Exer (M) +89,312 EDGAR
2026-06-04 Ivan Cheung Director Exer (M) +89,312 EDGAR
2026-06-04 RAYMOND DEBBANE Director Exer (M) +89,312 EDGAR
2026-06-04 Philippe Amouyal Director Exer (M) +89,312 EDGAR
2026-06-04 Judith L Swain Director Exer (M) +89,312 EDGAR
2026-06-04 Diane E. Sullivan Director Exer (M) +89,312 EDGAR
2026-06-04 SAM L BARKER Director Exer (M) +89,312 EDGAR
2026-05-08 International S.C.A. Artal Director Exer (M) +142,952,145 EDGAR
2026-05-04 Ivan Cheung Director Grant (A) +79,192 RSU EDGAR
2026-05-04 SAM L BARKER Director Grant (A) +79,192 opt EDGAR
2026-05-04 Philippe Amouyal Director Grant (A) +79,192 RSU EDGAR
2026-05-04 RAYMOND DEBBANE Director Grant (A) +79,192 RSU EDGAR
2026-05-04 CHRISTOPHER J SOBECKI Director Grant (A) +79,192 RSU EDGAR
2026-05-04 Judith L Swain Director Grant (A) +79,192 opt EDGAR
2026-05-04 Diane E. Sullivan Director Grant (A) +79,192 RSU EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
46 insiders · @ $2.22
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 C.V. Invus Director 283,154,744 $628.60M $20.25M 2 2021-01-05
2 International S.C.A. Artal Director 175,156,062 $388.85M $67.50M 2 2026-05-08
3 Administratiekantoor Westend Stichting Director 136,180,481 $302.32M $78.92M 3 2024-05-14
4 Pascal Minne Director 35,402,689 $78.59M $210.00M 1 2020-12-17
5 Ulys, L.L.C. Director 30,133,190 $66.90M $542.91M 2 2014-12-10
6 Invus Public Equities Advisors, LLC Director 21,321,961 $47.33M $1.65B 5 2018-06-29
7 Invus US Partners LLC Director 5,782,749 $12.84M $8.47M 2 2022-08-09
8 RAYMOND DEBBANE Director 3,533,960 $7.85M $5.43M 35 2026-06-04
9 Invus, L.P. Director 3,516,214 $7.81M $1.80B 6 2023-06-05
10 Invus Advisors, L.L.C. Director 3,006,678 $6.67M $104.03M 4 2018-06-18
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2024-08-15
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-08-15 COATS LONNEL Former Affiliate 300,000 $480.0K 2024-08-15 Charles Schwab & Co., Inc. EDGAR
2023-07-12 Seth Kiernan Former Affiliate 19,000 $43.9K 2023-07-12 Charles Schwab & Co., Inc. EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio4.7
P/S Ratio13.8
EV/EBITDA-38.2
TTM Revenue$0.1B
TTM Net Income$-0.0B
TTM EPS$-0.07
ROE-12.9%
Debt/Equity0.24